Clinical trials: Albuminuria
Hypertension, Diabetic Nephropathy
A Study in Patients With Diabetes Mellitus Type II of the Effect on Albuminuria of 24 Week Treatment With Valsartan, Benazepril, and Valsartan+Benazepril
The purpose of this study is to evaluate the efficacy of valsartan, benazepril or the combination of both in reduction of microalbuminuria in Type 2 diabetic patients.
- Trial name
- NCT00171119
- Testing
- valsartan
- Where
- Switzerland
- Volunteers
- 81 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Nephropathy
The Effects of Bindarit in Diabetic Nephropathy
The purpose of this study is to determine whether bindarit is effective to reduce albuminuria, compared to placebo, in nephropathic patients treated with irbesartan, as a background therapy.
- Trial name
- NCT01109212
- Testing
- Bindarit
- Where
- 6 sites in Italy, Slovenia
- Volunteers
- 100 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Sickle Cell Disease (SCD)
Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease
The goal of the study was to evaluate descriptively the effect of crizanlizumab + standard of care and standard of care alone on renal function in sickle cell disease patients ≥ 16 years with chronic kidney disease due to sickle…
- Trial name
- STEADFAST (NCT04053764)
- Testing
- Crizanlizuamb, Standard of Care
- Where
- 24 sites in United States, Brazil and 9 more
- Volunteers
- 58 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Diabetes
A Study for Prevention of Kidney Disease in Diabetic Patients (BENEDICT)
The BENEDICT study is conducted to examine the effects of an ACE inhibitor, calcium channel blockade, a combination of these, and placebo, in the prevention of micro- and macro-albuminuria in Type 2 diabetic patients.
- Trial name
- BENEDICT (NCT00235014)
- Testing
- trandolapril, trandolapril/verapamil, verapamil
- Volunteers
- 1,204 people
- Sponsor
- Abbott
Diabetic Kidney Disease, IgA Nephropathy
A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease
This is a phase II study to investigate the safety, preliminary efficacy and pharmacokinetics of SC0062 capsule in patients with chronic kidney disease (diabetic kidney disease and IgA nephropathy)with albuminuria compared to…
- Trial name
- NCT05687890
- Testing
- SC0062 low dose, SC0062 medium dose, SC0062 high dose
- Where
- China
- Volunteers
- 255 people
- Sponsor
- Biocity Biopharmaceutics Co., Ltd.
Diabetic Kidney Disease
SER150 vs Placebo in Diabetic Kidney Disease
This study is to assess the efficacy and safety of SER150 administered for 24 weeks as a 15 mg twice a day BID dose (except on Day 168 15 mg QD) in participants with type 2 diabetes (T2D) and albuminuria in treatment with either…
- Trial name
- NCT04881123
- Testing
- SER150
- Where
- 12 sites in Australia, New Zealand
- Volunteers
- 20 people
- Sponsor
- Serodus AS
Albuminuria
Effects of Amlodipine/Benazepril on Albuminuria in Hypertensive Patients With Type 2 Diabetes Mellitus
Type 2 diabetes mellitus is usually associated with high blood pressure, which is a risk factor for kidney disease. Aggressive blood pressure reduction is an important strategy to protect the kidney and reduce urinary protein…
- Trial name
- NCT00136773
- Testing
- amlodipine/benazepril
- Volunteers
- 332 people
- Sponsor
- Novartis
Chronic Kidney Disease
A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease
Researchers are looking for a better way to treat people who have chronic kidney disease (CKD), CKD is a condition in which the kidneys' ability to work properly gradually decreases over time.
- Trial name
- ALPINE 1 (NCT06522997)
- Testing
- BAY3283142
- Where
- 153 sites in United States, Argentina and 13 more
- Volunteers
- 1,222 people
- Sponsor
- Bayer
Type 2 Diabetes Mellitus, Albuminuria
NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria
Primary objective: To characterize the effects of 12 weeks treatment with study drug on albumin-creatinine ratio (ACR) in patients with type 2 diabetes and albuminuria Secondary objectives: To characterize the effect of study…
- Trial name
- NCT01547897
- Testing
- NOX-E36
- Where
- 24 sites in Czechia, Germany and 3 more
- Volunteers
- 76 people
- Sponsor
- TME Pharma AG
Blood Pressure, Albuminuria
Effect of NWT-03 on Blood Pressure
Part 2 of the study will assess the effect of 2g of NWT-03 (an egg-white protein hydrolysate) on systolic and diastolic blood pressure and flow-mediated dilation in a crossover designed study in healthy adults with mild…
- Trial name
- NCT02144740
- Testing
- NWT-03, an egg-white protein hydrolysate
- Where
- Ireland
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Newtricious R&D BV
Chronic Kidney Disease
Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria
This is a randomized, double-blind (DB), placebo controlled, crossover study with a two-period, two-sequence (2x2) design evaluating the efficacy and safety of 25 mg QD lorundrostat (an aldosterone synthase inhibitor [ASI]) in…
- Trial name
- NCT06150924
- Where
- 44 sites in United States
- Volunteers
- 60 people
- Sponsor
- Mineralys Therapeutics Inc.
Hypertensive Nephropathy, Auto Immune Disorders
ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases
This study investigates the safety and efficacy of ACE Reno, an oral transmucosal solution containing standardized bioactive peptides and amino acids, in patients with nephropathy of various etiologies and stages.
- Conditions
- Hypertensive Nephropathy, Auto Immune Disorders, Chronic Kidney Disease, Chronc Kidney Disease Stage 5
- Trial name
- ACE Reno (NCT07187713)
- Testing
- ACE Reno
- Where
- Egypt
- Volunteers
- 300 people
- Sponsor
- Ace Cells Lab Limited
Diabetes Mellitus, Type 2
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
Evaluate linagliptin in terms of glycemic control as defined by HbA1c after 24 weeks of treatment and in terms of renal efficacy as defined by changes in albuminuria (UACR) after 24 weeks of treatment.
- Trial name
- NCT01792518
- Testing
- Linagliptin 5mg
- Where
- 74 sites in United States, Canada and 10 more
- Volunteers
- 360 people
- Sponsor
- Boehringer Ingelheim
Hypertension
TELMA - Observational Study in Daily Medical Practice of the Effectiveness of Telmisartan for Treatment of Hypertension in Patients With and Without Confirmed Albuminuria in Belgium
This study was carried out in the context of daily medical practice to compare the effectiveness of telmisartan in the treatment of hypertension complicated or not with the presence of protein in the urine, which is called…
- Trial name
- NCT00886288
- Where
- 936 sites in Belgium
- Volunteers
- 2,874 people
- Sponsor
- Boehringer Ingelheim
Microalbuminuria, Proteinuria
To Assess the Effects of Valsartan on Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus
This study is designed to assess the efficacy of the different dosage forms of Valsartan[80, 160, and 320 mg] in reducing microalbuminuria/proteinuria in hypertensive patients with type 2 diabetes.
- Trial name
- NCT00550095
- Testing
- valsartan
- Where
- Egypt
- Volunteers
- 509 people
- Sponsor
- Novartis
Chronic Kidney Disease, Type 2 Diabetes
A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease
The purpose of this study is to evaluate the efficacy of ASP8232 in reducing Urinary Albumin to Creatinine Ratio (UACR) in subjects with Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) at 12 weeks compared to…
- Trial name
- ALBUM (NCT02358096)
- Testing
- ASP8232
- Where
- 57 sites in Czechia, Denmark and 7 more
- Volunteers
- 125 people
- Sponsor
- Astellas Pharma Europe B.V.
Chronic Kidney Disease, Diabetic Nephropathy
A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors
The study objective is to investigate the effects of three low doses of atrasentan on urinary albumin/creatinine ratio (UACR) levels in subjects with Type 2 diabetic nephropathy.
- Trial name
- NCT00920764
- Testing
- 0.25 mg Atrasentan QD, 0.75 mg Atrasentan QD, 1.75 mg Atrasentan QD
- Where
- 28 sites in United States, Puerto Rico
- Volunteers
- 92 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Diabetic Nephropathy
6-Month Safety And Efficacy Study Of TTP488 In Patients With Type 2 Diabetes And Persistent Albuminuria
Current research indicates that TTP488 may be a viable agent for the treatment of diabetic nephropathy. The purpose of this study is to determine the safety and efficacy of a six-month regimen of daily orally-administered TTP488…
- Trial name
- NCT00287183
- Testing
- PF-04494700 (TTP488)
- Where
- 19 sites in Canada
- Volunteers
- 110 people
- Sponsor
- Pfizer
Hypertension, Diabetes Mellitus, Type 2
ADDM Study - Amtrel and Co-Diovan in Type 2 Diabetes Mellitus Hypertension Patients With Microalbuminuria
The purpose of the study is to compare the change from baseline in blood pressures (DBP/SBP) to 16-week regimen between Amtrel® and Co-Diovan®. The secondary objectives were listed as the following.
- Conditions
- Hypertension, Diabetes Mellitus, Type 2, Albuminuria
- Trial name
- NCT01375322
- Testing
- Amlodipine+Benazepril, Valsartan+Hydrochlorothiazide
- Where
- 4 sites in Taiwan
- Volunteers
- 226 people
- Sponsor
- TSH Biopharm Corporation Limited
Hypertension, Type II Diabetes Mellitus
Phase IIa Study to Investigate the Efficacy and Safety of SPP635 in Diabetic and Hypertensive Patients With Albuminuria
This is a phase II a, double-blind, randomized, parallel-design, four-week study to investigate the efficacy, safety and tolerability of two different doses of SPP635 in type II diabetic patients with mild to moderate…
- Trial name
- NCT00561171
- Testing
- SPP635
- Where
- Ireland
- Volunteers
- 50 people
- Sponsor
- Speedel Pharma Ltd.